Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Rule 8.3 - Cyprotex PLC

FORM 8.3

DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE

(Rule 8.3 of the Takeover Code)

1. KEY INFORMATION

Name of person dealing (Note 1) R E Sneller

Company dealt in Cyprotex

Class of relevant security to Ord 0.1p share
which the dealings being
disclosed relate (Note 2)

Date of dealing 02/03/2010

2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

                                             Long Short

                                             Number (%) Number (%)

(1) Relevant securities             6,500,000 (3.63%)

(2) Derivatives (other than
options)

(3) Options and agreements to
purchase/sell

Total                                     6,500,000 (3.63%)

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:         Long              Short

                                             Number (%)     Number (%)

(1) Relevant securities

(2) Derivatives (other than
options)

(3) Options and agreements to
purchase/sell

Total

(c) Rights to subscribe (Note 3)

Class of relevant security: Details

3. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale    Number of securities    Price per unit (Note 5)

Purchase           500,000                       3.75p

(b) Derivatives transactions (other than options)

Product name, Long/short (Note 6) Number of securities (Note 7) Price per unit (Note 5)
e.g. CFD

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Product name, e.g call option
Writing, selling, purchasing,varying etc
Number of securities to which the option relates (note 7)
Exercise price
Type, e.g American,European etc
Expiry date
Option money paid / recieved per unit (note 5)

(ii) Exercising

Product name, Number of securities Exercise price per unit
e.g. call option (Note 5)

(d) Other dealings (including new securities) (Note 4)

Nature of transaction Details Price per unit (if
(Note 8) applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting
rights or future acquisition or disposal of any relevant securities to which
any derivative referred to on this form is referenced. If none, this should be
stated.

Is a Supplemental Form 8 attached? (Note 9)   YES/NO

Date of disclosure                                      03/03/2010

Contact name                                            R E Sneller

Telephone number                                     0131-275-2198

If a connected EFM, name of offeree/offeror
with which connected

If a connected EFM, state nature of
connection (Note 10)

Notes

The Notes on Form 8.3 can be viewed on the Takeover Panel's website at
www.thetakeoverpanel.org.uk

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close